Top

Osteoporosis International

Published in:

01-03-2007 | Original Article

Compliance with osteoporosis drug therapy and risk of fracture

Authors: D. Weycker, D. Macarios, J. Edelsberg, G. Oster

Published in: Osteoporosis International | Issue 3/2007

Abstract

Introduction

Patient compliance with osteoporosis drug therapy is often poor in clinical practice and may be associated with higher risk of fracture.

Methods

A nested case-control study was undertaken using a US health insurance claims database. The source population included all women aged ≥45 years who began drug therapy for osteoporosis. Cases consisted of those who experienced an osteoporosis-related fracture; they were matched to controls without osteoporosis-related fracture. Compliance with osteoporosis drug treatment was assessed in terms of the number of therapy-days received and medication possession ratio (MPR). Conditional logistic regression was employed to examine the relationship between compliance and fracture risk.

Results

A total of 453 women with osteoporosis-related fracture were identified and matched to 2,160 controls. Fracture risk was significantly lower for patients with >180 days of therapy [181–360 days: odds ratio (OR) = 0.70, 95% CI = 0.49–0.99; >360 days: OR = 0.65, 95% CI = 0.43–0.99) versus those with ≤30 days. Risk was also lower for patients with MPR ≥90% (OR = 0.70, 95% CI = 0.52–0.93) versus those with MPR <30%. Fracture risk decreased as compliance increased (p_trend < 0.05).

Conclusion

Among women initiating drug therapy for osteoporosis, better compliance is associated with reduced risk of fracture.

Available only for authorised users

U.S. Department of Health and Human Services. Bone health and osteoporosis: A report of the Surgeon General. Rockville, MD, U.S. Department of Health and Human Services, Office of the Surgeon General; 2004

Andrade SE, Sumit RM, Chan KA et al (2003) Low frequency of treatment of osteoporosis among postmenopausal women following a fracture. Arch Intern Med 163:2052–2057PubMedCrossRef

Melton LJ III, Thamer R, Ray NF et al (1997) Fractures attributable to osteoporosis: Report from the National Osteoporosis Foundation. J Bone Miner Res 12:16–23PubMedCrossRef

Eichner SF, Lloyd KB, Timpe EM (2003) Comparing therapies for postmenopausal osteoporosis prevention and treatment. Ann Pharmacother 37:744–746CrossRef

Feldstein AC, Nichols GA, Elmer PJ et al (2003) Older women with fractures: Patients falling through the cracks of guideline-recommended osteoporosis screening and treatment. J Bone Joint Surg 85A:2294–2302

Cuddihy MT, Gabriel SE, Crowson CS et al (2002) Osteoporosis intervention following distal forearm fractures: A missed opportunity? Arch Intern Med 162:421–426PubMedCrossRef

Freedman KB, Kaplan FS, Bilker WB et al (2000) Treatment of osteoporosis: Are physicians missing an opportunity? J Bone Joint Surg 82–A(8):1063–1070PubMed

Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861PubMedCrossRef

Kayser J, Ettinger B, Pressman A (2001) Postmenopausal hormonal support: Discontinuation of raloxifene versus estrogen. Menopause 8:328–332PubMedCrossRef

10.

Ettinger B, Pressman A, Schein J et al (1998) Alendronate use among 812 women: Prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharm 4:488–492

11.

Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003–1008PubMedCrossRef

12.

McCombs JS, Thiebaud P, McLaughlin-Miley C et al (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287PubMedCrossRef

13.

Siris ES, Rosen CJ, Harris ST, Abbott TA, Barr CE, Silverman SL. Adherence to bisphosphonate therapy: relationship to bone fractures at 24 months in women with postmenopausal osteoporosis. Presented at the National Osteoporosis Foundation 6th International Symposium. http://nof.confex.com/nof/2005/techprogram/P397.HTM. Accessed July 21, 2006

14.

Huybrechts KF, Ishak KJ, Caro J (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922–928PubMedCrossRef

15.

Health Insurance Portability and Accountability Act of 1996, 42 USC §1320–d2

16.

Public Welfare-Protection of Human Subjects; 45CFR 46 §46.101

17.

Black DM, Thompson DE, Bauer DC et al (2000) Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. J Clin Endocrinol Metab 85:4118–4124PubMedCrossRef

18.

Cummings SR, Black DM, Thompson DE et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the fracture intervention trial. JAMA 280:2077–2082PubMedCrossRef

19.

Ettinger B, Black DM, Mitlak BH et al (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trail. JAMA 282:637–645PubMedCrossRef

20.

Liberman UA, Weiss SR, Broll J et al (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437–1443PubMedCrossRef

21.

McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340PubMedCrossRef

22.

Osterberg L, Blaschke T (2005) Drug therapy: Adherence to medication. N Engl J Med 353:487–497PubMedCrossRef

23.

Sikka R, Xia F, Aubert RE (2005) Estimating medication persistency using administrative claims data. Am J Manag Care 11:449–457PubMed

Title: Compliance with osteoporosis drug therapy and risk of fracture
Authors: D. Weycker
D. Macarios
J. Edelsberg
G. Oster
Publication date: 01-03-2007
Publisher: Springer-Verlag
Published in: Osteoporosis International / Issue 3/2007
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-006-0230-y

At a glance: The STEP trials

Springer Medicine

Compliance with osteoporosis drug therapy and risk of fracture

Abstract

Introduction

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2007

Bone density in relation to alcohol intake among men and women in the United States

Failure of successful renal transplant to produce appropriate levels of 1,25-dihydroxyvitamin D

Height and bone mineral density in androgen insensitivity syndrome with mutations in the androgen receptor gene

Persistence, reproducibility, and cost-effectiveness of an intervention to improve the quality of osteoporosis care after a fracture of the wrist: results of a controlled trial

Vascular calcification and osteoporosis—from clinical observation towards molecular understanding

Peripheral bone mineral density and its predictors in healthy school girls from two different socioeconomic groups in Delhi